Angiogenesis therapy: Amidst the hype, the neglected potential for serious side effects

Circulation

Volumn 104, Issue 1, 2001, Pages 115-119

  Epstein, Stephen E ^a   Kornowski, Ran ^a   Fuchs, Shmuel ^a   Dvorak, Harold F ^b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Cells; Genes; Growth substances; Heart disease

Indexed keywords

VIRUS VECTOR;

ANGIOGENESIS; ARTERY OCCLUSION; ATHEROSCLEROSIS; BLOOD VESSEL PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

EID: 0035800094     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.104.1.115     Document Type: Review

References (73)

1. Review of preclinical and clinical results with vascular endothelial growth factors for therapeutic angiogenesis
2. FDA officials fault Penn team in gene therapy death
3. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
4. Vascular permeability factor/vascular endothelial growth factor: A multifunctional angiogenic cytokine
5. Selective induction of fibroblast growth factor receptor-1 mRNA after transient focal ischemia in the cerebral cortex of rats
6. Upregulation of fibroblast growth factor-receptor messenger RNA expression in rat brain following transient forebrain ischemia
7. Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin
8. Effects of acidic fibroblast growth factor on normal and ischemic myocardium
9. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization
10. Increased H202, vascular endothelial growth factor and receptors in the retina of the BBZ/Wor diabetic rat
11. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes
12. Induction of a fibrin-gel investment: An early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products
13. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
14. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines
15. Purification of a vascular permeability factor (VPF) from tumor cell conditioned medium
16. Human vascular permeability factor. Isolation from U937 cells
17. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis
18. Vascular permeability factor (VPF, VEGF) in tumor biology
19. Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo
20. Vascular permeability factor, an endothelial cell mitogen related to PDGF
21. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
22. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells
23. Purification and biological properties of vasculotropin, a new angiogenic cytokine
24. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells
25. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells
26. Vascular endothelial growth factor is a secreted angiogenic mitogen
27. The effects of growth factors on the day 13 chorioallantoic membrane (CAM): A study of VEGF165 and PDGF-BB
28. Tumors: Wounds that do not heal: Similarities between tumor stroma generation and wound healing
29. Healing of partial thickness porcine skin wounds in a liquid environment
30. Vascular permeability factor/endothelial growth factor (VPF/VEGF): Accumulation and expression in human synovial fluids and rheumatoid synovial tissue
31. Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: Rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth
32. Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells: Role in corpus luteum development
33. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation
34. Pathogenesis of ascites tumor growth: Vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation
35. Regulation of extravascular coagulation by microvascular permeability
36. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor
37. Fibrin containing gels induce angiogenesis: Implications for tumor stroma generation and wound healing
38. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor
39. Different pathways of macromolecule extravasation from hyperpermeable tumor vessels
40. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing
41. Angiopoietin-1 protects the adult vasculature against plasma leakage
42. Vascular development: Cellular and molecular regulation
43. Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells
44. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
45. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
46. VEGF gene delivery to muscle: Potential role for vasculogenesis in adults
47. VEGF gene delivery to myocardium: Deleterious effects of unregulated overexpression
48. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor
49. Smooth muscle cell abundance and fibroblast growth factors in coronary lesions of patients with nonfatal unstable angina: A clue to the mechanism of transformation from the stable to the unstable clinical state
50. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: Possible pathophysiological significance of VEGF in progression of atherosclerosis
51. Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries
52. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury
53. Characterization of in vivo gene transfer into the arterial wall mediated by the Sendai virus (hemagglutinating virus of Japan) liposomes: An effective tool for the in vivo study of arterial diseases
54. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo
55. Hypothesis. Vasa vasorum and neovascularization of human coronary arteries: A possible role in the pathophysiology of atherosclerosis
56. Intimal neovascularization in human coronary atherosclerosis: Its origin and pathophysiological significance
57. Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia
58. Angiogenesis in human coronary atherosclerotic plaques
59. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice
60. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion
61. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb
62. The pathophysiology of the collateral circulation (arteriogenesis)
63. Macrophages and atherosclerotic plaque stability
64. Vascular permeability factor: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity and promotes monocyte migration
65. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1
66. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension: Evidence for a maintenance role in quiescent adult endothelium
67. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries
68. Acidic and basic FGFs dilate arterioles of skeletal muscle through a NO-dependent mechanism
69. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts
70. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris
71. Basic fibroblast growth factor in patients with intermittent claudication: Results of a phase I trial
72. Catheter-based myocardial gene-transfer utilizing nonfluoroscopic electromechanical left ventricular mapping
73. Electromagnetic-guidance for catheter-based trans-endocardial injection: A platform for myocardial angiogenesis therapy: Results in normal and ischemic porcine model